Testing effectiveness (Phase 2)WithdrawnNCT01244438What this trial is testingStudy of FP-1039 in Subjects With Endometrial CancersWho this might be right forEndometrial Cancers With FGFR2 Mutations Five Prime Therapeutics, Inc.